So when I went to the Pulmonary doc with Drew on Friday, I was talking to his doctor for a few minutes about the approval of Kalydeco. Anyone whose been reading this blog with any frequency knows of my hope for this drug to work for him. Since it was just approved on Jan.31, it was my first opportunity to talk realistically about the possibility of getting him on it. She said that she really didn't expect that it would work for him because his mutations we're "gating" mutations. Wait, what? I thought that R560T was a Class 3 mutation, just like G551D which was tested with Kalydeco and showed remarkable results. She said that she had an app from Vertex Pharmaceuticals that allows you to look up mutations and learn a little bit more about what class they fall into and what kind of problems they cause. HELLO! (The iPhone app is called CF Gene, for anyone who cares). So she pulls up R560T and it shows it as a Class 4 or 5 mutation, just like F508del. This is contrary to everything I've ever read or seen about his R560T mutation, and I told her that. The great thing about our CF doctors is that they want to work with you and learn and grow in their understanding with you. It has never been, for us anyway, a I'm the doctor so I'm right kind of relationship. So she asked me to send her what I had seen about R560T being a class 3 mutation that could benefit from the new drug. I was able to send her several articles, including some from the National Institute of Health and other medical papers from renown research hospitals. She emailed me back today saying this:
There seems to be conflicting information because I see where they call R560T a class 3 mutation and another place where they refer to a gating defect, but I also found an article where they stained the R560T region and did not find the protein on the cell surface. This suggests that it is a class 4 or 5 mutation. I'll check with Dr. Clancy to see if he knows which source is most reliable. I know you will be disappointed if Kalydeco does not work for Drew. I think Kalydeco is just the tip of the iceburg. We are getting closer to having drugs for other mutations and Kalydeco's success will help push research for other drugs along.We didn't know if Kalydeco would actually work for Drew or not anyway, and she's right that I will be disappointed if it doesn't work for him, but I'm really curious now to see what class his mutation falls into. I hope that the app is wrong and I am right
No comments:
Post a Comment